Enrollment

• Helus Pharma has appointed Michael Halstead, the former President of Intra-Cellular Therapies, as its new Chief Executive Officer. • The company successfully completed patient enrollment for its Phase 3 APPROACH study evaluating the drug candidate HLP003. • To support late-stage development and future commercialization, Helus Pharma has secured $50 million in new funding.

Republicans have latched on to the announcement after Trump’s lie-laden speech, but experts say DHS’s data is ‘designed to create a false argument’Donald Trump and his allies quickly seized on an announcement from Mikie Sherrill, the New Jersey governor, on Tuesday that 6,600 noncitizens had registered to vote because of a software error, and fewer than 400 of them voted, using thedisclosure to escalate false claims that there are scores of noncitizens on the voter rolls.Trump seized on thenews days after he said in a primetime speech that the Department of Homeland Security identified 278,000 noncitizens on the voter rolls in New Jersey and three other states. But a Guardian review of the letters DHS sent the states shows the agency expressed less certainty about the number and has offered no explanation of its methodology. Continue reading...

• Helus Pharma has completed enrollment ahead of schedule for the Phase 3 APPROACH study, which evaluates HLP003 as an adjunctive treatment for Major Depressive Disorder. • The company is continuing enrollment for EMBRACE, a second pivotal study within the Phase 3 PARADIGM Program, while rolling participants into the EXTEND study for long-term safety data. • This milestone is significant as HLP003 has previously been granted Breakthrough Therapy designation, signaling its potential to provide substantial improvement over existing therapies.